Ani pharmaceuticals reports record first quarter 2023 financial results and raises full-year 2023 guidance
Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (nasdaq: anip) (ani or the company) today announced business highlights and financial results for the three months ended march 31, 2023. “our outstanding performance in the first quarter of 2023 further demonstrates ani’s ability to compete and win across our core business segments. we are pleased to announce record quarterly net revenues and adjusted non-gaap ebitda and a significant increase to full-year 2023 guidance. importantly, we continue to invest behind the launch of our foundational rare disease asset, purified cortrophin gel. we continually strive to strengthen the team, improve our approach to servicing patient, physician and payor needs, and increase access to acth therapy for patients in need. these efforts have resulted in the further acceleration of our launch momentum with record quarterly new cases initiated in the first quarter of 2023, record monthly new patient starts and cases initiated in april 2023 and first quarter net revenues of cortrophin gel of $16.3 million in-line with our expectations,” stated nikhil lalwani, president and ceo of ani. “robust results in our generics, established brands and others segment showcases ani’s ability to leverage our u.s. manufacturing footprint and our agility in operations to deliver timely solutions to our customers. during the past two years, we have enhanced ani’s operational excellence by combining long-standing strengths in manufacturing and our strong gmp track record with best-in-class research and development capabilities, all with a ‘patient-first’ orientation. this has enabled us to capture market demand arising from the numerous supply disruptions impacting patient access to much-needed medicines. we are pleased with the strong start to 2023 and look forward to continuing to serve patients in need and working hard to build on the growth momentum throughout the year,” concluded lalwani. first quarter 2023 financial highlights: net revenues were $106.8 million compared to $64.5 million in q1 2022. gaap net income available to common shareholders was $1.0 million, and diluted gaap income per share was $0.06. adjusted non-gaap ebitda was $33.0 million compared to $4.3 million in q1 2022. adjusted non-gaap diluted earnings per share was $1.17, compared to diluted loss per share of $(0.12) in q1 2022. cash and cash equivalents were $67.8 million, net accounts receivable was $174.7 million, and face value of debt was $296.3 million as of march 31, 2023. first quarter and recent business highlights: rare disease business update revenues for cortrophin gel totaled $16.3 million in the first quarter, in line with internal expectations. the company continues to see significant growth momentum as evidenced by a record number of new cases initiated in the first quarter of 2023 and new monthly records for new patient starts and new cases in april 2023. importantly, the acth category, which had been declining since 2019, has experienced ten consecutive months of year-on-year growth from june 2022 – march 2023. in fact, the acth market has continued to see double-digit growth in volumes in each month of the first quarter of 2023. the company has ramped-up promotional efforts to continue to build awareness of cortrophin gel through peer-to-peer education programs across target indications of rheumatology, neurology and nephrology. in addition, the company has executed upon its previously discussed plans to modestly expand its sales force, and its pulmonology sales force is now fully staffed and operational. this strong first-quarter performance is in line with expectations, and thus the company is maintaining its 2023 revenue guidance for cortrophin gel of $80 million to $90 million, representing 92% - 116% year-over-year growth. rare disease remains a critical focus area for achieving future growth, and the company continues to actively explore opportunities to acquire or establish partnerships to leverage its rare disease platform. generics business, established brands and others update sales of generic pharmaceuticals products grew 29.7% year-over-year in the first quarter of 2023 and increased 10% sequentially from a strong fourth quarter in 2022. the company’s generics business is well positioned for delivering sustainable growth driven by a strong r&d engine launching new products. today, ani retains a top ten ranking for new anda approvals and a number two ranking for competitive generic therapy approvals. in addition, ani received multiple abbreviated new drug applications (andas) approvals, including nitrofurantoin oral suspension usp, 25 mg/5 ml and colestipol hydrochloride tablets usp, 1 g. ani’s enhanced focus on operational excellence and u.s. based manufacturing sites have enabled the company to capture numerous opportunities arising from supply disruptions in both generics and established brands. in addition, the company augmented its strong gmp (good manufacturing practices) track record with the successful conclusion of a u.s food and drug administration (fda) audit at its new jersey site with zero 483s and no actions indicated (nai) status. as previously announced, manufacturing operations ceased at the oakville, ontario, site in january 2023, with the successful relocation of the oakville products to u.s. facilities. discussions with potential buyers for the oakville site are ongoing. first quarter 2023 financial results three months ended march 31, 2023 2022 change % change 63,713 49,107 14,606 29.7 % 26,743 14,078 12,665 90.0 % 90,456 63,185 27,271 43.2 % 16,330 1,292 15,038 nm (1) 106,786 64,477 42,309 65.6 % net revenues for generic pharmaceutical products were $63.7 million during the three months ended march 31, 2023, an increase of 29.7% compared to $49.1 million for the same period in 2022, driven by increased volume from the annualization of 2022 launches and a favorable product mix. net revenues for established brand pharmaceutical products, royalties, and other pharmaceutical services were $26.7 million during the three months ended march 31, 2023, an increase of 90.0% compared to $14.1 million for the same period in 2022, driven by an increase in volume. net revenues of rare disease pharmaceutical products, which consist entirely of sales of cortrophin gel, were $16.3 million during the three months ended march 31, 2023, an increase of $15.0 million from $1.3 million for the same period in 2022. this increase was driven by increased volume as the product was launched in late january 2022. operating expenses increased by 15.8% to $96.9 million for the three months ended march 31, 2023, from $83.7 million in the prior year period as a result of the following factors: for the three months ended march 31, 2023, cost of sales increased to $37.7 million from $34.3 million for the same period in 2022, an increase of $3.4 million, or 10.0%. the increase is primarily due to a shift in product mix and increased volumes of sales of generic and rare disease pharmaceutical products. during the three months ended march 31, 2022, we recognized $3.8 million in cost of sales representing the excess of fair value over cost for inventory acquired in acquisitions and subsequently sold during the three months ended march 31, 2022. there are no comparable expenses in the three months ended march 31, 2023. research and development expenses increased from $5.3 million to $5.9 million, an increase of $0.7 million or 12.3%, primarily due to year over year timing of work associated with generic projects coupled with an increase associated with projects related to cortrophin gel in the three months ended march 31, 2023. selling, general, and administrative expenses increased from $28.8 million to $36.5 million, an increase of $7.7 million, or 26.6%, primarily due to a $3.4 million increase in sales and marketing expenses related to cortrophin gel and increased headcount related costs tempered by a $0.7 million decrease in transaction expenses related to the novitium acquisition. depreciation and amortization increased slightly in the first quarter of 2023 to $14.7 million from $14.6 million in the comparable quarter in 2022, an increase of $0.1 million. the company recognized a contingent consideration fair value adjustment of $1.0 million and $0.8 million expense in the three months ended march 31, 2023, and 2022, respectively, related to the 2021 acquisition of novitium pharma llc. the company recognized restructuring activities of $1.1 million of expense in the three months ended march 31, 2023, in relation to the closure of our oakville, ontario, canada facility. costs included severance and other employee benefits costs of $0.2 million, $0.7 million of accelerated depreciation costs, and $0.2 million for other miscellaneous costs accrued in 2022. net income available to common shareholders for the first quarter of 2023 was $1.0 million as compared to net loss of $(20.5) million in the prior year period. diluted income per share for the three months ended march 31, 2023, was $0.06 compared to diluted gaap loss per share of $(1.27) in the prior year period. adjusted non-gaap diluted earnings per share was $1.17 in the first quarter of 2023 compared to a diluted loss per share of $(0.12) in the first quarter of 2022. for reconciliations of adjusted non-gaap ebitda and adjusted non-gaap diluted earnings per share to the most directly comparable gaap financial measure, please see table 3 and table 4, respectively. liquidity as of march 31, 2023, the company had $67.8 million in unrestricted cash and cash equivalents plus $174.7 million in net accounts receivable. the company had $296.3 million (face value) in outstanding debt as of march 31, 2023. 2023 financial guidance updates - raised total company net revenue guidance to between $385.0 million and $410.0 million as compared to previously issued guidance of $360.0 million to $385.0 million. revised guidance represents approximately 22% to 30% growth as compared to $316.4 million recognized in 2022; - maintained cortrophin gel specific revenue guidance of between $80.0 million to $90.0 million, representing 92% to 116% growth as compared to $41.7 million recognized in 2022; - total company non-gaap gross margin to between 60.0% and 62.5% as compared to previously issued guidance of 59.5% and 61.0%; - raised total company adjusted non-gaap ebitda to between $97.0 million and $107.0 million as compared to previously issued guidance of $78.0 million and $88.0 million. revised guidance represents approximately 74% to 91% growth as compared to $55.9 million recognized in 2022; and - raised adjusted non-gaap diluted earnings per share to between $2.99 and $3.45 as compared to previously issued guidance of $2.09 and $2.59. in addition, ani currently anticipates between 16.8 million and 17.1 million shares outstanding and an effective tax rate of approximately 24.0% prior to any federal tax reform. conference call as previously announced, ani management will host its first quarter 2023 conference call as follows: date may 8, 2023 time 8:30 a.m. et toll free (u.s.) 800-245-3047 global 203-518-9765 webcast (live and replay) www.anipharmaceuticals.com, under the “investors” section a replay of the conference call will be available within two hours of the call’s completion and will remain accessible for one week by dialing 888-274-8330 and entering access code 534116. non-gaap financial measures adjusted non-gaap ebitda ani’s management considers adjusted non-gaap ebitda to be an important financial indicator of ani’s operating performance, providing investors and analysts with a useful measure of operating results unaffected by non-cash stock-based compensation and differences in capital structures, tax structures, capital investment cycles, ages of related assets, and compensation structures among otherwise comparable companies. management uses adjusted non-gaap ebitda when analyzing company performance. beginning in the fourth quarter of 2022, ani no longer excludes expense for in-process research & development or cortrophin gel pre-launch charges and sales and marketing expenses from its non-gaap results. historically, the company excluded these charges. these changes have been made to align with views expressed by the u.s. securities and exchange commission. prior periods have been recast to reflect these changes. adjusted non-gaap ebitda is defined as net income (loss), excluding tax expense or benefit, interest expense, (net), other expense, (net), depreciation, amortization, the excess of fair value over cost of acquired inventory, non-cash stock-based compensation expense, novitium transaction expenses, contingent consideration fair value adjustment, and certain other items that vary in frequency and impact on ani’s results of operations. adjusted non-gaap ebitda should be considered in addition to, but not in lieu of, net income or loss reported under gaap. a reconciliation of adjusted non-gaap ebitda to the most directly comparable gaap financial measure is provided below. ani is not providing a reconciliation for the forward-looking full year 2023 adjusted ebitda guidance because it does not currently have sufficient information to accurately estimate all of the variables and individual adjustments for such reconciliation, including “with” and “without” tax provision information. as such, ani’s management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results. adjusted non-gaap net income (loss) ani’s management considers adjusted non-gaap net income (loss) to be an important financial indicator of ani’s operating performance, providing investors and analysts with a useful measure of operating results unaffected by the excess of fair value over cost of acquired inventory sold, non-cash stock-based compensation, non-cash interest expense, depreciation and amortization, novitium transaction expenses, contingent consideration fair value adjustment, and certain other items that vary in frequency and impact on ani’s results of operations. management uses adjusted non-gaap net income (loss) when analyzing company performance. beginning in the fourth quarter of 2022, ani no longer excludes expense for in-process research & development or cortrophin gel pre-launch charges and sales and marketing expenses from its non-gaap results. historically, the company excluded these charges. these changes have been made to align with views expressed by the u.s. securities and exchange commission. prior periods have been recast to reflect these changes. adjusted non-gaap net income (loss) is defined as net income (loss), plus the excess of fair value over cost of acquired inventory sold, non-cash stock-based compensation expense, novitium transaction expenses, non-cash interest expense, depreciation and amortization expense, contingent consideration fair value adjustment, and certain other items that vary in frequency and impact on ani’s results of operations, less the tax impact of these adjustments calculated using an estimated statutory tax rate. management will continually analyze this metric and may include additional adjustments in the calculation in order to provide further understanding of ani’s results. adjusted non-gaap net income (loss) should be considered in addition to, but not in lieu of, net income (loss) reported under gaap. a reconciliation of adjusted non-gaap net income (loss) to the most directly comparable gaap financial measure is provided below. adjusted non-gaap diluted (loss)/earnings per share ani’s management considers adjusted non-gaap diluted (loss)/earnings per share to be an important financial indicator of ani’s operating performance, providing investors and analysts with a useful measure of operating results unaffected by the excess of fair value over cost of acquired inventory sold, non-cash stock-based compensation, non-cash interest expense, depreciation and amortization, novitium transaction expenses, contingent consideration fair value adjustment, and certain other items that vary in frequency and impact on ani’s results of operations. management uses adjusted non-gaap diluted (loss)/earnings per share when analyzing company performance. adjusted non-gaap diluted (loss)/earnings per share is defined as adjusted non-gaap net income (loss), as defined above, divided by the diluted weighted average shares outstanding during the period. management will continually analyze this metric and may include additional adjustments in the calculation in order to provide further understanding of ani’s results. adjusted non-gaap diluted (loss)/earnings per share should be considered in addition to, but not in lieu of, diluted earnings or loss per share reported under gaap. a reconciliation of adjusted non-gaap diluted (loss)/earnings per share to the most directly comparable gaap financial measure is provided below. ani is not providing a reconciliation for the forward-looking full year 2023 adjusted diluted earnings per share guidance because it does not currently have sufficient information to accurately estimate all of the variables and individual adjustments for such reconciliation, including “with” and “without” tax provision information. as such, ani’s management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results. about ani ani pharmaceuticals, inc. (nasdaq: anip) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. our team is focused on delivering sustainable growth by building a successful purified cortrophin® gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our north american manufacturing capabilities. for more information, please visit our website www.anipharmaceuticals.com. forward-looking statements to the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the private securities litigation reform act of 1995. such statements include, but are not limited to, those relating to the commercialization and potential sales of the product and any additional product launches from the company’s generic pipeline, other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates. uncertainties and risks may cause the company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. uncertainties and risks include, but are not limited to: risks that we may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of our products from both domestic and overseas sources due to supply chain disruptions or for any other reason; delays or failure in obtaining and maintaining approvals by the fda of the products we sell; changes in policy or actions that may be taken by the fda and other regulatory agencies, including drug recalls; the ability of our manufacturing partners to meet our product demands and timelines; our dependence on single source suppliers of ingredients due to the time and cost to validate a second source of supply; acceptance of our products at levels that will allow us to achieve profitability; our ability to develop, license or acquire, and commercialize new products; the level of competition we face and the legal, regulatory and/or legislative strategies employed by our competitors to prevent or delay competition from generic alternatives to branded products; our ability to protect our intellectual property rights; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the impact of any litigation to which we are, or may become, a party; our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; our ability to maintain the services of our key executives and other personnel; whether we experience disruptions to our operations resulting from the closure of our oakville, ontario manufacturing plant, including the transition of certain products manufactured there to our other facilities which has been completed, or have difficulties finding a buyer for the plant and property; and general business and economic conditions, such as inflationary pressures, geopolitical conditions including the conflict between russia and the ukraine, and the effects and duration of outbreaks of public health emergencies, such as covid-19, and other risks and uncertainties that are described in ani’s annual report on form 10-k, quarterly reports on form 10-q, and other periodic reports filed with the securities and exchange commission. more detailed information on these and additional factors that could affect the company’s actual results are described in the company’s filings with the securities and exchange commission (sec), including its most recent annual report on form 10-k and quarterly reports on form 10-q, as well as other filings with the sec. all forward-looking statements in this news release speak only as of the date of this news release and are based on the company’s current beliefs, assumptions, and expectations. the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. financial tables follow ani pharmaceuticals, inc. and subsidiaries table 1: us gaap statement of operations (unaudited, in thousands, except per share amounts) three months ended march 31, 2023 2022 $ 106,786 $ 64,477 37,708 34,271 5,924 5,274 36,468 28,817 14,700 14,557 961 753 1,130 - 96,891 83,672 9,895 (19,195 ) (7,696 ) (6,613 ) (34 ) (89 ) 2,165 (25,897 ) (726 ) 5,767 $ 1,439 $ (20,130 ) (406 ) (405 ) $ 1,033 $ (20,535 ) $ 0.06 $ (1.27 ) $ 0.06 $ (1.27 ) 16,392 16,137 16,531 16,137 ani pharmaceuticals, inc. and subsidiaries table 2: us gaap balance sheets (unaudited, in thousands) march 31, 2023 december 31, 2022 $ 67,757 $ 48,228 - 5,006 174,713 165,438 103,654 105,355 3,735 3,827 8,020 8,020 6,874 8,387 364,753 344,261 70,553 75,958 (27,278 ) (32,712 ) 43,275 43,246 80,956 81,363 238,791 251,635 28,221 28,221 9,228 11,361 $ 765,224 $ 760,087 $ 850 $ 850 32,687 29,305 8,957 9,307 13,051 10,312 8,607 10,872 34,108 33,399 22,761 - 4,804 5,394 125,825 99,439 285,457 285,669 13,258 35,058 1,202 1,381 425,742 421,547 24,850 24,850 1 1 (8,643 ) (5,094 ) 408,395 403,901 (96,252 ) (97,286 ) 11,131 12,168 314,632 313,690 $ 765,224 $ 760,087 ani pharmaceuticals, inc. and subsidiaries table 3: adjusted non-gaap ebitda calculation and us gaap to non-gaap reconciliation (unaudited, in thousands) reconciliation of certain adjusted non-gaap accounts: net revenues cost of sales (excluding depreciation and amortization) selling, general, and administrative expenses research and development expenses three months ended march 31, three months ended march 31, three months ended march 31, three months ended march 31, three months ended march 31, 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 $ 1,439 $ (20,130 ) as reported: $ 106,786 $ 64,477 $ 37,708 $ 34,271 $ 36,468 $ 28,817 $ 5,924 $ 5,274 7,696 6,613 34 89 726 (5,767 ) 14,700 14,557 961 753 1,130 - 1,647 - impact of canada operations(1) (565 ) - (1,416 ) - (1,861 ) - (64 ) - 4,338 3,237 stock-based compensation - - (151 ) (145 ) (3,980 ) (2,839 ) (207 ) (253 ) - 3,829 excess of fair value over cost of acquired inventory - - - (3,829 ) - - - - 342 1,092 novitium transaction expenses - - - - (342 ) (1,092 ) - - $ 33,013 $ 4,273 as adjusted: $ 106,221 $ 64,477 $ 36,141 $ 30,297 $ 30,285 $ 24,886 $ 5,653 $ 5,021 table 4: adjusted non-gaap net income and adjusted non-gaap diluted earnings per share reconciliation (unaudited, in thousands, except per share amounts) three months ended march 31, 2023 2022 $ 1,033 $ (20,535 ) 987 953 14,700 14,557 961 753 1,130 - 1,647 - 4,338 3,237 - 3,829 342 1,092 (5,785 ) (5,861 ) $ 19,353 $ (1,975 ) 16,531 16,137 16,531 16,137 $ 1.17 $ (0.12 )
